Union européenne - français - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - immunosuppresseurs - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. le traitement de sévère, active et progressive de la polyarthrite rhumatoïde chez les adultes non précédemment traités par le méthotrexate. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita réduit le taux de progression des lésions articulaires mesurés par radiographie et améliore la fonction physique, lorsqu'il est administré en association avec le méthotrexate. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita peut être administré en monothérapie en cas d'intolérance au méthotrexate ou lorsque la poursuite du traitement avec le méthotrexate, est inadéquate (pour l'efficacité en monothérapie, voir la section 5. l'adalimumab n'a pas été étudié chez les patients âgés de moins de 2 ans. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita réduit le taux de progression de l'atteinte articulaire périphérique tel que mesuré par rayons x dans les patients avec polyarticular symétrique sous-types de la maladie (voir la section 5. 1) et améliore la fonction physique. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 et 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - adalimumabum - solution injectable dans une seringue préremplie - adalimumabum 40 mg, saccharum, polysorbatum 80, acidum aceticum glaciale, natrii hydroxidum corresp. natrium 0.26 mg, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew), morbus crohn bei erwachsenen sowie kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, hidradenitis suppurativa, uveitis - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - adalimumabum - solution injectable en stylo prérempli - adalimumabum 40 mg, saccharum, polysorbatum 80, acidum aceticum glaciale, natrii hydroxidum corresp. natrium max. 0.26 mg, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - la polyarthrite rhumatoïde, l'arthrite juvénile idiopathique, d'arthrite, de rhumatisme psoriasique, de spondylarthrite ankylosante (maladie de bechterew), la maladie de crohn chez l'adulte, la colite ulcéreuse, le psoriasis chez l'adulte - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - adalimumabum - solution injectable dans une seringue préremplie - adalimumabum 20 mg, saccharum, polysorbatum 80, acidum aceticum glaciale, natrii hydroxidum corresp. natrium 0.13 mg, aqua ad iniectabile q.s. ad solutionem pro 0.4 ml. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew), morbus crohn bei erwachsenen sowie kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, hidradenitis suppurativa, uveitis - biotechnologika

Canada - français - Health Canada

amgen canada inc - adalimumab - solution - 50mg - adalimumab 50mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

amgen canada inc - adalimumab - solution - 50mg - adalimumab 50mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

amgen canada inc - adalimumab - solution - 50mg - adalimumab 50mg - disease-modifying antirheumatic agents

Union européenne - français - EMA (European Medicines Agency)

ammtek - glibenclamide - diabète sucré - les médicaments utilisés dans le diabète - amglidia est indiqué pour le traitement de diabète néonatal, pour une utilisation chez les nouveau-nés, les nourrissons et les enfants. sulfamides hypoglycémiants comme amglidia ont été montré pour être efficace dans les patients avec des mutations dans les gènes codant pour les cellules β sensibles à l'atp canal potassium et le chromosome 6q24 liées au diabète néonatal transitoire.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - adalimumabum - solution injectable dans une seringue préremplie - adalimumabum 20 mg, saccharum, polysorbatum 80, acidum lacticum, natrii hydroxidum corresp. natrium max. 0.11 mg, aqua ad iniectabile q.s. ad solutionem pro 0.2 ml. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew), morbus crohn bei erwachsenen sowie kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, hidradenitis suppurativa, uveitis - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - adalimumabum - solution injectable dans une seringue préremplie - adalimumabum 40 mg, saccharum, polysorbatum 80, acidum lacticum, natrii hydroxidum corresp. natrium max. 0.22 mg, aqua ad iniectabile q.s. ad solutionem pro 0.4 ml. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew), morbus crohn bei erwachsenen sowie kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, hidradenitis suppurativa, uveitis - biotechnologika